Journal: Frontiers in Pediatrics
Article Title: Noninvasive salivary biomarkers (PTX3, calprotectin, and IL-8) for early-onset neonatal pneumonia: case-control differences and exploratory discrimination
doi: 10.3389/fped.2026.1747967
Figure Lengend Snippet: Salivary biomarkers modestly enrich for blood-culture-positive bacteremia within EONP. (A – C) Salivary PTX3, calprotectin, and IL-8 in culture-positive vs. culture-negative EONP cases (medians with IQRs; Mann–Whitney P < 0.001, =0.003, =0.002, respectively). (D – F) ROC curves for bacteremia detection using single salivary markers with optimal cutoffs (PTX3 ≥ 2.51 ng/mL; calprotectin ≥14.57 ng/mL; IL-8 ≥ 18.97 pg/mL), yielding AUCs 0.725, 0.682, and 0.689, respectively. The solid line denotes the ROC curve and the dashed lines indicate the 95% confidence interval (lower and upper limits). (G) ROC curves for the three-marker combined model (logistic regression using PTX3, calprotectin, and IL-8). The combined model achieved an apparent AUC of 0.702, with internally validated AUCs of 0.706 (5-fold cross-validation) and 0.702 (LOOCV), indicating stable but moderate enrichment performance.
Article Snippet: Salivary PTX3, calprotectin, and IL-8 concentrations were measured using commercial ELISA kits according to the manufacturers' instructions: PTX3 with the QuantikineTM Human Pentraxin 3 Immunoassay (R&D Systems, Cat. DPTX30B); calprotectin with the Quantikine® Human Calprotectin Heterodimer Immunoassay (R&D Systems, Cat. DS8900); and IL-8 with the LEGEND MAXTM High Sensitivity Human IL-8 ELISA Kit (BioLegend, Cat. 431517).
Techniques: MANN-WHITNEY, Marker, Biomarker Discovery